Sign in →

Test Code MNB Manganese, Blood

Reporting Name

Manganese, B

Useful For

Evaluation of central nervous system symptoms, similar to Parkinson disease, in manganese (Mn) miners and processors

 

Characterization of liver cirrhosis

 

Therapeutic monitoring in treatment of cirrhosis, parenteral nutrition-related Mn toxicity, and environmental exposure to Mn

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Whole blood


Specimen Required


Patient Preparation: High concentrations of gadolinium and iodine are known to interfere with most metal tests. If either gadolinium- or iodine-containing contrast media has been administered, a specimen should not be collected for 96 hours.

Container/Tube: Royal blue top (EDTA) Vacutainer plastic trace element blood collection tube

Specimen Volume: 0.3 mL

Collection Instructions:

1. See Metals Analysis Specimen Collection and Transport for complete instructions.

2. Send whole blood specimen in original tube. Do not aliquot.


Specimen Minimum Volume

0.2 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Whole blood Refrigerated (preferred) 28 days
  Ambient  28 days
  Frozen  28 days

Reference Values

4.7-18.3 ng/mL

Day(s) Performed

Tuesday

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

83785

LOINC Code Information

Test ID Test Order Name Order LOINC Value
MNB Manganese, B 5681-2

 

Result ID Test Result Name Result LOINC Value
89120 Manganese, B 5681-2

Interpretation

Whole blood or serum concentrations in combination with brain magnetic resonance imaging scans and neurological assessment may be used to detect excessive exposure.  Values between 1 and 2 times the upper limit of normal may be due to differences in hematocrit and normal biological variation and should be interpreted with caution before concluding that hypermanganesemia is contributing to the disease process. Values greater than twice the upper limit of normal correlate with disease. For longitudinal monitoring, sampling no more frequently than the half-life of the element (40 days) should be used.

Clinical Reference

1. Levy BS, Nassetta WJ. Neurologic effects of manganese in humans: A review. Int J Occup Environ Health. 2003;9(2):153-163. doi:10.1179/oeh.2003.9.2.153

2. Choi Y, Park JK, Park NH, et al. Whole blood and red blood cell manganese reflected signal intensities of T1-weighted magnetic resonance images better than plasma manganese in liver cirrhotics. J Occup Health. 2005 Feb;47(1):68-73. doi:10.1539/joh.47.68

3. Sanotsky Y, Lesyk R, Fedoryshyn L, Komnatska I, Matviyenko Y, Fahn S, et al. Manganic encephalopathy due to "Ephedrone" abuse. Mov Disord. 2007;22(9):1337-1343. doi:10.1002/mds.21378

4. Jiang Y, Zheng W, Long L, et al. Brain magnetic resonance imaging and manganese concentrations in red blood cells of smelting workers: search for biomarkers of manganese exposure. Neurotoxicology. 2007;28(1):126-135. doi:10.1016/j.neuro.2006.08.005

5. Guilarte T, Chen M, McGlothan J, et al. Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Exp Neurol. 2006;202(2):381-390. doi:10.1016/j.expneurol.2006.06.015

6. Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds: Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023

7. O'Neal SL, Zheng W. Manganese toxicity upon overexposure: a decade in review. Curr Environ Health Rep. 2015;2(3):315-328. doi:10.1007/s40572-015-0056-x

Report Available

2 to 8 days

Method Name

Triple-Quadrupole Inductively Coupled Plasma-Mass Spectrometry (ICP-MS/MS)